Roche Holding (LSE:0QOK) - Cotización, noticias y análisis

Resumen de acción 0QOK

Roche Holding AG opera en el sector farmacéutico y de diagnóstico en Europa, Norteamérica, Latinoamérica, Asia, África, Australia y Oceanía.

Acerca de la empresa

0QOK fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	3/6
Past Performance	4/6
Financial Health	4/6
Dividends	5/6

Recompensas

Cotiza un 67.1% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 8.65%

Paga dividendo fiable de 4.39%

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

Tiene un alto nivel de endeudamiento

Competidores de Roche Holding AG

AstraZeneca

LSE:AZN

UK£188.4b

GSK

LSE:GSK

UK£70.5b

Hikma Pharmaceuticals

LSE:HIK

UK£4.3b

HUTCHMED (China)

AIM:HCM

UK£2.6b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Roche Holding
Historical stock prices
Current Share Price	CHF214.52
52 Week High	CHF298.40
52 Week Low	CHF213.80
Beta	0.15
1 Month Change	-6.05%
3 Month Change	-8.76%
1 Year Change	-23.85%
3 Year Change	-28.39%
5 Year Change	-17.45%
Change since IPO	8.29%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	0QOK	GB Pharmaceuticals	Mercado GB
7D	-2.2%	2.2%	1.3%
1Y	-23.9%	6.3%	3.5%

Rentabilidad vs. Industria: 0QOK obtuvo unos resultados inferiores a los del sector UK Pharmaceuticals , que el año pasado arrojó un rendimiento del 5%.

Rentabilidad vs. Mercado: 0QOK obtuvo unos resultados inferiores a los del mercado UK, que fue del 0.6% el año pasado.

Volatilidad de los precios

Is 0QOK's price volatile compared to industry and market?
0QOK volatility
0QOK Average Weekly Movement	2.8%
Pharmaceuticals Industry Average Movement	7.4%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.4%
10% least volatile stocks in GB Market	2.7%

Precio estable de las acciones: 0QOK no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de 0QOK (3%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1896	103,605	Thomas Schinecker	www.roche.com

Roche Holding AG opera en el sector farmacéutico y de diagnóstico en Europa, Norteamérica, Latinoamérica, Asia, África, Australia y Oceanía. La empresa ofrece productos farmacéuticos en las áreas terapéuticas de anemia, tumores sanguíneos y sólidos, dermatología, hemofilia, enfermedades inflamatorias y autoinmunes, trastornos neurológicos, oftalmología, trastornos respiratorios y trasplantes. También está desarrollando productos para diversas áreas terapéuticas.

Resumen de fundamentos de Roche Holding AG

¿Cómo se comparan los beneficios e ingresos de Roche Holding con su capitalización de mercado?
Estadísticas fundamentales de 0QOK
Capitalización bursátil	CHF172.83b
Beneficios(TTM)	CHF11.50b
Ingresos (TTM)	CHF60.44b

14.8x

Ratio precio-beneficio (PE)

2.8x

Ratio precio-ventas (PS)

¿Está 0QOK sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 0QOK
Ingresos	CHF60.44b
Coste de los ingresos	CHF15.60b
Beneficio bruto	CHF44.84b
Otros gastos	CHF33.35b
Beneficios	CHF11.50b

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	14.42
Margen bruto	74.19%
Margen de beneficio neto	19.02%
Ratio deuda/patrimonio	88.0%

¿Cómo se ha desempeñado 0QOK a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

4.5%

Rentabilidad actual por dividendo

67%

Ratio de pagos

Resumen de acción 0QOK

Recompensas

Análisis de riesgos

Competidores de Roche Holding AG

LSE:AZN

UK£188.4b

LSE:GSK

UK£70.5b

LSE:HIK

UK£4.3b

AIM:HCM

UK£2.6b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Recent updates

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Upcoming dividend of CHF9.60 per share

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Full year 2023 earnings released: EPS: CHF14.39 (vs CHF15.53 in FY 2022)

Dividend increased to CHF9.60

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration

Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy

United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO)

Roche Holding AG Confirms Outlook for 2023

Roche Announces Roche IL-6 Is the First Immunoassay Approved to Aid Sepsis Diagnosis in Newborns

Roche Announces New Clinical and Real-World Data for Orevus (Ocrelizumab)

Roche Holding AG Announces Late-Breaking Data from the Phase III Ocarina III Study as an Investigational Twice-Yearly, 10-Minute Subcutaneous Injection on Pharmacokinetic, Biomarker, and Mri Measures in Patients with Relapsing or Primary Progressive Multiple Sclerosis

Roche Presents Positive Results from the Primary Analysis of the Ongoing Rainbowfish Study Assessing the Efficacy and Safety of Evrysdi

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

Roche’S Alecensa Delivers Unprecedented Phase III Results for People with ALK-positive early-stage lung cancer

Roche Holding AG Tecentriq Becomes the First Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy Available to Patients in Great Britain, Reducing Treatment Time to Just Minutes

Roche Provides Update on Phase III Skyscraper-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer

New minor risk - Earnings quality

Roche Holding AG Confirms Earnings Guidance for the Year 2023

Roche Announces New Clinical and Real-World Data for Vabysmo at ASRS Reveal Improved Outcomes for People with Two Leading Causes of Vision Loss

Roivant Sciences Reportedly Near Deal to Sell Stomach Drug to Roche for over $7 Billion

Roche Announces Positive Phase III Results for Roche’s OCREVUS (ocrelizumab) Twice a Year, 10-minute Subcutaneous Injection in Patients with Multiple Sclerosis

European Commission Approves Roche Holding AG's Fixed-Term Columvi (Glofitamab) for People with Relapsed or Refractory Diffuse Large B-Cell L-Cell Lymphoma

Roche Receives FDA Clearance for Additional Alzheimer's Disease Cerebrospinal Fluid Assays, Supporting Timely Diagnosis and Treatment Decision-Making

Roche Looking to Sell or Shut Down Vacaville, California Plant

Roche Announces U.S. Food and Drug Administration Accepted Supplemental Biologics License Application for Vabysmo

Upcoming dividend of CHF9.50 per share at 3.6% yield

Roche Announces Positive New Data from Two Global phase III studies, BALATON and COMINO

Full year 2022 earnings released: EPS: CHF15.53 (vs CHF16.39 in FY 2021)

Roche Announces Positive Data from Global Phase III Programme for Crovalimab in PNH, A Rare Life-Threatening Blood Condition

Roche Holding AG Announces Executive Appointments

Roche Launches COVID-19 PCR Test to Detect the Fast Spreading XBB.1.5 Omicron Sub-Variant

Roche Announces the Phase III IMbrave050 Study Met Its Primary Endpoint of Recurrence-Free Survival (RFS) At the Prespecified Interim Analysis

Roche Announces the European Commission Approval of Xofluza for the Treatment and Prevention of Influenza in Children Aged One Year and Above

FDA approves Roche Holding AG’s Lunsumio, a first-in-class bispecific antibody, to treat people with relapsed or refractory follicular lymphoma

Roche Presents New Data Demonstrating the Potential Benefit of Glofitamab and Lunsumio as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma

Roche Holding AG Announces its Alzheimer’s Disease Cerebrospinal Fluid (CSF) Assays Receive FDA Clearance, Supporting More Accurate and Timely Diagnosis

Roche Diagnostics North America Announces Brad Moore as President, Effective January 1, 2023